A second-generation AR bifunctional degrader for drug-resistant prostate cancer. ARV-766 is Arvinas’ second bifunctional CRL4 CRBN E3 ligase-based androgen receptor (AR) degrader to enter the clinic for the treatment of prostate cancer (PCa), after ARV-110 (bavdegalutamide) . The glutarimide recruiting element is notable as it is simpler than [...]
A Second-Generation AR Bifunctional Degrader for Drug-Resistant Prostate Cancer
ARV-766
oral AR-degrading PROTAC Ph. II for adv. prostate cancer from CRBN-based E3 recruiter + AR ligand AACR, April 2023 Arvinas, New Haven, CT
Loading...
